See more : Regulus Resources Inc. (REG.V) Income Statement Analysis – Financial Results
Complete financial analysis of Comera Life Sciences Holdings, Inc. (CMRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Comera Life Sciences Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- United Utilities Group PLC (UUGWF) Income Statement Analysis – Financial Results
- Saikaya Department Store Co.,Ltd. (8254.T) Income Statement Analysis – Financial Results
- Chongqing Rural Commercial Bank Co., Ltd. (601077.SS) Income Statement Analysis – Financial Results
- Lachish Industries Ltd (LHIS.TA) Income Statement Analysis – Financial Results
- Ratch Group Public Company Limited (RGPCF) Income Statement Analysis – Financial Results
Comera Life Sciences Holdings, Inc. (CMRA)
About Comera Life Sciences Holdings, Inc.
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 633.10K | 319.83K | 442.92K |
| Cost of Revenue | 210.39K | 161.01K | 104.41K |
| Gross Profit | 422.71K | 158.82K | 338.51K |
| Gross Profit Ratio | 66.77% | 49.66% | 76.43% |
| Research & Development | 1.74M | 1.75M | 1.26M |
| General & Administrative | 10.65M | 3.94M | 1.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 10.65M | 3.94M | 1.20M |
| Other Expenses | 0.00 | -76.74K | 2.03K |
| Operating Expenses | 12.39M | 5.69M | 2.47M |
| Cost & Expenses | 12.60M | 5.86M | 2.57M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 20.39K | 0.00 | 0.00 |
| Depreciation & Amortization | 93.95K | 88.82K | 89.75K |
| EBITDA | -17.89M | -5.36M | -2.04M |
| EBITDA Ratio | -2,825.23% | -1,754.07% | -460.08% |
| Operating Income | -11.97M | -5.54M | -2.13M |
| Operating Income Ratio | -1,890.69% | -1,730.79% | -480.34% |
| Total Other Income/Expenses | -6.03M | 83.85K | 2.03K |
| Income Before Tax | -18.00M | -5.45M | -2.13M |
| Income Before Tax Ratio | -2,843.79% | -1,704.58% | -479.88% |
| Income Tax Expense | 0.00 | -160.59K | -116.55K |
| Net Income | -18.00M | -5.29M | -2.13M |
| Net Income Ratio | -2,843.79% | -1,654.37% | -479.88% |
| EPS | -1.76 | -0.28 | -0.11 |
| EPS Diluted | -1.76 | -0.28 | -0.11 |
| Weighted Avg Shares Out | 10.45M | 19.09M | 19.09M |
| Weighted Avg Shares Out (Dil) | 10.45M | 19.09M | 19.09M |
Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option
WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a proprietary drug-delivery technology to improve patient access, safety, and convenience, today announced the closing of...
Comera Life Sciences Announces Process Exploring Strategic Alternatives
WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that...
Comera Life Sciences Appoints Dorothy Clarke to Board of Directors
WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to...
Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights
– Final stage of technical evaluation near completion in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company –
Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference
WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera's SQore™...
These Are the ONLY 7 Penny Stocks to Consider in August 2023
Some of the most promising penny stocks can have multi-bagger potential over the long haul. After all, the combination of low prices, strong catalysts, and potentially high returns can be appealing.
Comera Life Sciences Announces Publication of Study Reinforcing Caffeine's Viscosity Reducing Capabilities
Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies
Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights
– Advanced to final stage of technical evaluation in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company –
Comera Life Sciences Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore™ Platform
WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced a significant expansion of its...
Comera Life Sciences Announces Collaboration with Quality Chemical Laboratories to Secure Proprietary Supply of SQore Excipients
– Ownership of proprietary sourcing for U.S.-manufactured lead SQore excipients allows for full control over supply chain and greater flexibility to support product development needs –
Source: https://incomestatements.info
Category: Stock Reports